Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

Vasant Narasimhan, Novartis CEO, joins 'Money Movers' to discuss the company's quarterly earnings results. Amazon listing tariff prices is a 'hostile and political act,' White House says Movies Over 4 ...

These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

Further, Novartis has shown a willingness to buy back shares at generally neutral time periods. Turning to management specifically, Vasant Narasimhan replaced eight-year veteran Joe Jimenez as CEO ...

Q: Can you provide insights on Novartis' exposure to tariffs and the impact on your financial outlook? A: Vasant Narasimhan, CEO, explained that Novartis has accounted for potential tariffs in its ...

Further, Novartis has shown a willingness to buy back shares at generally neutral time periods. Turning to management specifically, Vasant Narasimhan replaced eight-year veteran Joe Jimenez as CEO ...

Novartis' Narasimhan, who has long been bullish on his firm's growth in the U.S. market, said at the time that tariffs were a consideration but not the driving factor in the firm's decision.